Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept vs Aflibercept T&E Regimens in Neovascular AMD
ChiCTR2400087042Phase 4Completed
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of conbercept and aflibercept in exudative macular degeneration (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Best-Corrected Visual Acuity. Started Jul 2024; status: completed.
02
Drugs
conberceptaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2400087042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087042.